No Data
Head to Head Contrast: Candel Therapeutics (NASDAQ:CADL) and Elevation Oncology (NASDAQ:ELEV)
Candel Therapeutics (NASDAQ:CADL – Get Rating) and Elevation Oncology (NASDAQ:ELEV – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesse
Candel Therapeutics (NASDAQ:CADL) Trading Down 5.3%
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) fell 5.3% during mid-day trading on Wednesday . The company traded as low as $3.20 and last traded at $3.21. 6,148 shares were traded d
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (Me
Candel Therapeutics Receives Positive European Opinion on Orphan Designation Application for Tumor Drug; Shares Rise
11:12 AM EDT, 09/15/2022 (MT Newswires) -- Candel Therapeutics (CADL) said Thursday it received a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products on the o
Candel Gets European Orphan Drug Designation for Brain, Spinal Cord Tumor Treatment
Candel Therapeutics (NASDAQ:CADL) on Thursday said a European drug regulator committee had given a positive recommendation to grant an orphan drug designation to the company's CAN-2409 therapy for the
Candel Therapeutics Receives Orphan Drug Designation From European Medicines Agency For CAN-2409 In Glioma
Candel Therapeutics Receives Orphan Drug Designation From European Medicines Agency For CAN-2409 In Glioma
Candel Therapeutics: John Canepa Decided to Pursue Other Interests and Spend More Time With Family >CADL
Candel Therapeutics Names Jason Amello as Chief Fincl Officer >CADL
Candel Therapeutics Names Garrett Nichols as Chief Medical Officer >CADL
Looking Into Candel Therapeutics's Return On Capital Employed
Benzinga Pro data, Candel Therapeutics (NASDAQ:CADL) reported Q2 sales of $31 thousand. Earnings fell to a loss of $4.15 million, resulting in a 374.71% decrease from last quarter. In Q1, Candel Thera
Loading...
